MIB2: A Key Player in The Ubiquitin System (G142678)

Target Name: MIB2

NCBI ID: G142678

MIB2

MIB2: A Key Player in The Ubiquitin System

MIB2 (MIB E3 ubiquitin protein ligase 2, transcript variant 1) is a protein that is expressed in a variety of cell types, including human tissues and organs. It is a key player in the ubiquitin system, a system that is responsible for the degradation of damaged or unnecessary proteins. MIB2 plays a crucial role in this process by catalyzing the transfer of the ubiquitin protein from the target protein to the ubiquitin protein ligase E1, which then leads to the ubiquitination and subsequent degradation of the target protein.

MIB2 is a 19-kDa protein that is composed of 256 amino acid residues. It has a molecular weight of 21.1 kDa and a calculated pI of 5.3. MIB2 is expressed in a variety of tissues and organs, including the liver, spleen, lung, kidney, and heart. It is also expressed in the brain and nervous system, which suggests that it may be involved in the regulation of these systems.

One of the unique features of MIB2 is its ability to interact with the ubiquitin protein E1. This interaction allows MIB2 to catalyze the transfer of the ubiquitin protein from the target protein to the ubiquitin protein ligase E1. This process is critical for the regulation of protein levels and for the maintenance of cellular homeostasis.

MIB2 has been shown to play a role in a variety of cellular processes, including cell signaling, DNA repair, and inflammation. For example, MIB2 has been shown to be involved in the regulation of the Notch signaling pathway, which is a critical pathway that is involved in the regulation of cell growth, differentiation, and survival.

In addition to its role in the ubiquitin system, MIB2 has also been shown to play a role in the regulation of cellular signaling pathways. For example, MIB2 has been shown to be involved in the regulation of the PI3K/Akt signaling pathway, which is involved in the regulation of cell signaling and survival.

MIB2 has also been shown to play a role in the regulation of DNA repair pathways. For example, MIB2 has been shown to be involved in the regulation of the DNA double-strand break repair pathway, which is involved in the regulation of DNA repair and the prevention of genetic mutations.

In addition to its role in cellular signaling and DNA repair pathways, MIB2 has also been shown to play a role in the regulation of inflammation. For example, MIB2 has been shown to be involved in the regulation of the NF-kappa-B signaling pathway, which is involved in the regulation of inflammation and immune responses.

Despite its importance role in a variety of cellular processes, MIB2 is not yet a well-established drug target. There are currently no drugs that are specifically designed to target MIB2, and research is being conducted to determine the potential utility of MIB2 as a drug target.

In conclusion, MIB2 is a protein that is expressed in a variety of cell types and plays a crucial role in the ubiquitin system. Its ability to interact with the ubiquitin protein E1 and its involvement in a variety of cellular processes make it an attractive candidate for drug targeting. Further research is needed to determine the potential utility of MIB2 as a drug target.

Protein Name: MIB E3 Ubiquitin Protein Ligase 2

Functions: E3 ubiquitin-protein ligase that mediates ubiquitination of Delta receptors, which act as ligands of Notch proteins. Positively regulates the Delta-mediated Notch signaling by ubiquitinating the intracellular domain of Delta, leading to endocytosis of Delta receptors

The "MIB2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIB2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets